EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 211 / Numéro 1 (2017) Biologie Aujourd'hui, 211 1 (2017) 51-67 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 211, Numéro 1, 2017
Page(s) 51 - 67
Section Microbiote intestinal et santé (Journée Claude Bernard 2016)
DOI https://doi.org/10.1051/jbio/2017009
Publié en ligne 6 juillet 2017
  • Belcheva A., Irrazabal T., Robertson S.J., Streutker C., Maughan H., Rubino S., Moriyama E.H., Copeland J.K., Surendra A., Kumar S., Green B., Geddes K., Pezo R.C., Navarre W.W., Milosevic M., Wilson B.C., Girardin S.E., Wolever T.M.S., Edelmann W., Guttman D.S., Philpott D.J., Martin A. (2014). Gut Microbial Metabolism Drives Transformation of Msh2-Deficient Colon Epithelial Cells. Cell, 158, 288–299. [CrossRef] [PubMed] [Google Scholar]
  • Blair P.J., Riley J.L., Levine B.L., Lee K.P., Craighead N., Francomano T., Perfetto S.J., Gray G.S., Carreno B.M., June C.H. (1998). CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol, 160, 12–15. [PubMed] [Google Scholar]
  • Burnet M. (1957). Cancer : a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J., 1, 841–847. [CrossRef] [PubMed] [Google Scholar]
  • Clemente J.C., Ursell L.K., Parfrey L.W., Knight R. (2012). The impact of the gut microbiota on human health : an integrative view. Cell, 148, 1258–1270. [CrossRef] [PubMed] [Google Scholar]
  • Collins J., Borojevic R., Verdu E.F., Huizinga J.D., Ratcliffe E.M. (2014). Intestinal microbiota influence the early postnatal development of the enteric nervous system. Neurogastroenterol Motil, 26, 98–107. [CrossRef] [PubMed] [Google Scholar]
  • Costello E.K., Lauber C.L., Hamady M., Fierer N., Gordon J.I., Knight R. (2009). Bacterial community variation in human body habitats across space and time. Science, 326, 1694–1697. [CrossRef] [PubMed] [Google Scholar]
  • Daillère R., Vétizou M., Waldschmitt N., Yamazaki T., Isnard C., Poirier-Colame V., Duong C.P.M., Flament C., Lepage P., Roberti M.P., Routy B., Jacquelot N., Apetoh L., Becharef S., Rusakiewicz S., Langella P., Sokol H., Kroemer G., Enot D., Roux A., Eggermont A., Tartour E., Johannes L., Woerther P.-L., Chachaty E., Soria J.-C., Golden E., Formenti S., Plebanski M., Madondo M., Rosenstiel P., Raoult D., Cattoir V., Boneca I.G., Chamaillard M., Zitvogel L. (2016). Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 45, 931–943. [CrossRef] [PubMed] [Google Scholar]
  • Dapito D.H., Mencin A., Gwak G.-Y., Pradere J.-P., Jang M.-K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R., Lefkowitch J.H., Bower M., Friedman R., Sartor R.B., Rabadan R., Schwabe R.F. (2012). Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell, 21, 504–516. [CrossRef] [PubMed] [Google Scholar]
  • de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., Plummer M. (2012). Global burden of cancers attributable to infections in 2008 : a review and synthetic analysis. Lancet Oncol, 13, 607–615. [CrossRef] [PubMed] [Google Scholar]
  • Dubin K., Callahan M.K., Ren B., Khanin R., Viale A., Ling L., No D., Gobourne A., Littmann E., Huttenhower C., Pamer E.G., Wolchok J.D. (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun., 7, 10391. [CrossRef] [PubMed] [Google Scholar]
  • Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. (2008). Adoptive cell therapy for patients with metastatic melanoma : evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 26, 5233–5239. [CrossRef] [PubMed] [Google Scholar]
  • El Kaoutari A., Armougom F., Raoult D., Henrissat B. (2014). [Gut microbiota and digestion of polysaccharides]. Médecine Sci MS, 30, 259–265. [Google Scholar]
  • Emadi A., Jones R.J., Brodsky R.A. (2009). Cyclophosphamide and cancer : golden anniversary. Nat Rev Clin Oncol, 6, 638–647. [CrossRef] [PubMed] [Google Scholar]
  • Farache J., Koren I., Milo I., Gurevich I., Kim K.-W., Zigmond E., Furtado G.C., Lira S.A., Shakhar G. (2013) Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. Immunity, 38, 581–595. [CrossRef] [PubMed] [Google Scholar]
  • Garrett W.S., Gallini C.A., Yatsunenko T., Michaud M., DuBois A., Delaney M.L., Punit S., Karlsson M., Bry L., Glickman J.N., Gordon J.I., Onderdonk A.B., Glimcher L.H. (2010). Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe, 8, 292–300. [CrossRef] [PubMed] [Google Scholar]
  • Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.-J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 369, 134–144. [CrossRef] [PubMed] [Google Scholar]
  • Hanahan D., Weinberg R.A. (2011). Hallmarks of cancer : the next generation. Cell, 144, 646–674. [CrossRef] [PubMed] [Google Scholar]
  • Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J.M., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbé C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 711–723. [CrossRef] [PubMed] [Google Scholar]
  • Hooper L.V., Littman D.R., Macpherson A.J. (2012). Interactions between the microbiota and the immune system. Science, 336, 1268–1273. [CrossRef] [PubMed] [Google Scholar]
  • Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. (2012). Nature, 486, 207–214. [Google Scholar]
  • Hviid A., Svanström H., Frisch M. (2011). Antibiotic use and inflammatory bowel diseases in childhood. Gut, 60, 49–54. [CrossRef] [PubMed] [Google Scholar]
  • Iida N., Dzutsev A., Stewart C.A., Smith L., Bouladoux N., Weingarten R.A., Molina D.A., Salcedo R., Back T., Cramer S., Dai R.-M., Kiu H., Cardone M., Naik S., Patri A.K., Wang E., Marincola F.M., Frank K.M., Belkaid Y., Trinchieri G., Goldszmid R.S. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 342, 967–970. [CrossRef] [PubMed] [Google Scholar]
  • Kamada N., Chen G.Y., Inohara N., Núñez G. (2013). Control of pathogens and pathobionts by the gut microbiota. Nat. Immunol, 14, 685–690. [Google Scholar]
  • Krummel M.F., Allison J.P. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med, 182, 459–465. [CrossRef] [PubMed] [Google Scholar]
  • Kwon E.D., Hurwitz A.A., Foster B.A., Madias C., Feldhaus A.L., Greenberg N.M., Burg M.B., Allison J.P. (1997). Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA, 94, 8099–8103. [CrossRef] [Google Scholar]
  • Lagier J.-C., Armougom F., Million M., Hugon P., Pagnier I., Robert C., Bittar F., Fournous G., Gimenez G., Maraninchi M., Trape J.-F., Koonin E.V., LaScola B., Raoult D. (2012). Microbial culturomics : paradigm shift in the human gut microbiome study. Clin Microbiol Infect, 18, 1185–1193. [CrossRef] [PubMed] [Google Scholar]
  • Leach D.R., Krummel M.F., Allison J.P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271, 1734-1736. [CrossRef] [PubMed] [Google Scholar]
  • Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. (1991). CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med, 174, 561–569. [CrossRef] [PubMed] [Google Scholar]
  • Maynard C.L., Elson C.O., Hatton R.D., Weaver C.T. (2012). Reciprocal interactions of the intestinal microbiota and immune system. Nature, 489, 231–241. [CrossRef] [PubMed] [Google Scholar]
  • Mowat A.M., Agace W.W. (2014). Regional specialization within the intestinal immune system. Nat Rev Immunol, 14, 667–685. [CrossRef] [PubMed] [Google Scholar]
  • Paulos C.M., Wrzesinski C., Kaiser A., Hinrichs C.S., Chieppa M., Cassard L., Palmer D.C., Boni A., Muranski P., Yu Z., Gattinoni L., Antony P.A., Rosenberg S.A., Restifo N.P. (2007). Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest, 117, 2197–2204. [CrossRef] [PubMed] [Google Scholar]
  • Pédron T., Mulet C., Dauga C., Frangeul L., Chervaux C., Grompone G., Sansonetti P.J. (2012) A crypt-specific core microbiota resides in the mouse colon. MBio, 3(3). doi :10.1128/mBio.00116-12. [Google Scholar]
  • Perkins D., Wang Z., Donovan C., He H., Mark D., Guan G., Wang Y., Walunas T., Bluestone J., Listman J., Finn P.W. (1996). Regulation of CTLA-4 expression during T cell activation. J Immunol, 156, 4154–4159. [PubMed] [Google Scholar]
  • Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., Mende D.R., Li J., Xu J., Li S., Li D., Cao J., Wang B., Liang H., Zheng H., Xie Y., Tap J., Lepage P., Bertalan M., Batto J.-M., Hansen T., Le Paslier D., Linneberg A., Nielsen H.B., Pelletier E., Renault P., Sicheritz-Ponten T., Turner K., Zhu H., Yu C., Li S., Jian M., Zhou Y., Li Y., Zhang X., Li S., Qin N., Yang H., Wang J., Brunak S., Doré J., Guarner F., Kristiansen K., Pedersen O., Parkhill J., Weissenbach J., MetaHIT Consortium, Bork P., Ehrlich S.D., Wang J. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 464, 59–65. [CrossRef] [PubMed] [Google Scholar]
  • Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.-T., Humphrey R., Hoos A., Wolchok J.D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 364, 2517–2526. [Google Scholar]
  • Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J., Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.-J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 369, 134–144. [CrossRef] [PubMed] [Google Scholar]
  • Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., Larkin J., Lorigan P., Neyns B., Blank C.U., Hamid O, Mateus C., Shapira-Frommer R., Kosh M., Zhou H., Ibrahim N., Ebbinghaus S., Ribas A., KEYNOTE-006 investigators. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med, 372, 2521–2532. [Google Scholar]
  • Rossini A., Rumio C., Sfondrini L., Tagliabue E., Morelli D., Miceli R., Mariani L., Palazzo M., Ménard S., Balsari A. (2006). Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. Cancer Res, 66, 6219–6224. [CrossRef] [Google Scholar]
  • Rubio-Godoy V., Dutoit V., Zhao Y., Simon R., Guillaume P., Houghten R., Romero P., Cerottini J.-C., Pinilla C., Valmori D. (2002). Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL. J Immunol, 169, 5696–5707. [CrossRef] [PubMed] [Google Scholar]
  • Rutkowski M.R., Stephen T.L., Svoronos N., Allegrezza M.J., Tesone A.J., Perales-Puchalt A., Brencicova E., Escovar-Fadul X., Nguyen J.M., Cadungog M.G., Zhang R., Salatino M., Tchou J., Rabinovich G.A., Conejo-Garcia J.R. (2015). Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell, 27, 27–40. [CrossRef] [PubMed] [Google Scholar]
  • Schloissnig S., Arumugam M., Sunagawa S., Mitreva M., Tap J., Zhu A., Waller A., Mende D.R., Kultima J.R., Martin J., Kota K., Sunyaev S.R., Weinstock G.M., Bork P. (2013). Genomic variation landscape of the human gut microbiome. Nature, 493, 45–50. [CrossRef] [PubMed] [Google Scholar]
  • Schneider H., Downey J., Smith A., Zinselmeyer B.H., Rush C., Brewer J.M., Wei B., Hogg N., Garside P., Rudd C.E. (2006). Reversal of the TCR stop signal by CTLA-4. Science, 313, 1972–1975. [CrossRef] [PubMed] [Google Scholar]
  • Schneider H., Smith X., Liu H., Bismuth G., Rudd C.E. (2008). CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur J Immunol, 38, 40–47. [CrossRef] [PubMed] [Google Scholar]
  • Schreiber R.D., Old L.J., Smyth M.J. (2011). Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion. Science, 331, 1565–1570. [CrossRef] [PubMed] [Google Scholar]
  • Sears C.L., Garrett W.S. (2014). Microbes, Microbiota and Colon Cancer. Cell Host Microbe, 15, 317–328. [CrossRef] [PubMed] [Google Scholar]
  • Sergentanis T.N., Zagouri F., Zografos G.C. (2010). Is antibiotic use a risk factor for breast cancer? A meta-analysis. Pharmacoepidemiol Drug Saf, 19, 1101–1107. [CrossRef] [PubMed] [Google Scholar]
  • Sistigu A., Viaud S., Chaput N., Bracci L., Proietti E., Zitvogel L. (2011). Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol, 33, 369–383. [CrossRef] [PubMed] [Google Scholar]
  • Sivan A., Corrales L., Hubert N., Williams J.B., Aquino-Michaels K., Earley Z.M., Benyamin F.W., Lei Y.M., Jabri B., Alegre M.-L., Chang E.B., Gajewski T.F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 350, 1084–1089. [CrossRef] [PubMed] [Google Scholar]
  • Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., Hollmann T.J., Bruggeman C., Kannan K., Li Y., Elipenahli C., Liu C., Harbison C.T., Wang L., Ribas A., Wolchok J.D., Chan T.A. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J. Med, 371, 2189–2199. [Google Scholar]
  • Sommer F., Bäckhed F. (2013). The gut microbiota–masters of host development and physiology. Nat Rev Microbiol, 11, 227–238. [CrossRef] [PubMed] [Google Scholar]
  • Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541–547. [CrossRef] [PubMed] [Google Scholar]
  • Ubeda C., Pamer E.G. (2012). Antibiotics, microbiota, and immune defense. Trends Immunol, 33, 459–466. [CrossRef] [PubMed] [Google Scholar]
  • van Vliet M.J., Harmsen H.J.M., de Bont E.S.J.M., Tissing W.J.E. (2010). The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog, 6, e1000879. [CrossRef] [PubMed] [Google Scholar]
  • Vétizou M., Pitt J.M., Daillère R., Lepage P., Waldschmitt N., Flament C., Rusakiewicz S., Routy B., Roberti M.P., Duong C.P.M., Poirier-Colame V., Roux A., Becharef S., Formenti S., Golden E., Cording S., Eberl G., Schlitzer A., Ginhoux F., Mani S., Yamazaki T., Jacquelot N., Enot D.P., Bérard M., Nigou J., Opolon P., Eggermont A., Woerther P.-L., Chachaty E., Chaput N., Robert C., Mateus C., Kroemer G., Raoult D., Boneca I.G., Carbonnel F., Chamaillard M., Zitvogel L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350, 1079–1084. [CrossRef] [PubMed] [Google Scholar]
  • Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., Enot D.P., Pfirschke C., Engblom C., Pittet M.J., Schlitzer A., Ginhoux F., Apetoh L., Chachaty E., Woerther P.-L., Eberl G., Bérard M., Ecobichon C., Clermont D., Bizet C., Gaboriau-Routhiau V., Cerf-Bensussan N., Opolon P., Yessaad N., Vivier E., Ryffel B., Elson C.O., Doré J., Kroemer G., Lepage P., Boneca I.G., Ghiringhelli F., Zitvogel L. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 342, 971–976. [CrossRef] [PubMed] [Google Scholar]
  • Walunas T.L., Bakker C.Y., Bluestone J.A. (1996). CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med, 183, 2541–2550. [CrossRef] [PubMed] [Google Scholar]
  • Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1, 405–413. [CrossRef] [PubMed] [Google Scholar]
  • Wang J.-L., Chang C.-H., Lin J.-W., Wu L.-C., Chuang L.-M., Lai M.-S. (2014). Infection, antibiotic therapy and risk of colorectal cancer : a nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int J Cancer, 135, 956–967. [CrossRef] [PubMed] [Google Scholar]
  • Wang L., Ribas A., Wolchok J.D., Chan T.A. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med, 371, 2189–2199. [CrossRef] [PubMed] [Google Scholar]
  • Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. (1995). Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science, 270, 985–988. [CrossRef] [PubMed] [Google Scholar]
  • Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., Iwakura Y., Oshima K., Morita H., Hattori M., Hattori M., Honda K., Ishikawa Y., Hara E., Ohtani N. (2013). Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 499, 97–101. [CrossRef] [PubMed] [Google Scholar]
  • Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol, 8, 59–73. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.